Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by quest13on Sep 20, 2019 3:42pm
258 Views
Post# 30149501

RE:RE:RE:RE:RE:RE:Fear

RE:RE:RE:RE:RE:RE:FearFear and Trepidation and Expectation of Plenty are all in our hearts as shareholders at this time.

We are about to receive the results of the super important Phase 3 trial. We have been told on or about 2019/09/30.

if the results are good (which most shareholders including some billionaires) are expecting (hoping for) then all else pales into insignificance and whether you fear $11 million or $160 million it does not matter as very substantial funds will be available to the company to get rid of petty nuiscance items.

on the other hand if results are not good at all we all write off what we have invested (Pretty much totally).

there are multiple in between points such as potential vascular improvement and anti inflammation and eGfr etc etc. in those cases not all is lost but there is a reduction in the value of our investment which the market will take a while to ponder before we know what our shares are really worth.

in any case we will soon know and I for one have a big enough investment that I will either be very happy or very unhappy. I have not bet the farm but have as big an investement as I can afford to lose and I believe that the science will resukt in a very good payoff.
Bullboard Posts